The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

It can be hard to tell for sure if you have atopic dermatitis, also known as eczema ... and topical ruxolitinib (Opzelura). They are used for moderate to severe AD in those over 12.

It is facing competition in the category from non-steroid drugs like Incyte’s JAK inhibitor Opzelura (ruxolitinib), approved for atopic dermatitis in 2021, although, that requires twice-daily ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first ...

Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that its topical ...

Lawrence Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the importance of shared decision-making in atopic dermatitis treatment, emphasizing ...

Discover a study that aimed to compare the effects of antimicrobial–corticosteroid combination therapy with corticosteroid ...

with Opzelura's approval for pediatric Atopic Dermatitis (AD) seen as a modest growth driver. Notably, Incyte maintains a strong financial position with more cash than debt on its balance sheet ...